Overall survival of patients with de Novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: A population-based cohort study of systemically treated patients
OS has doubled over ten years, for patients diagnosed with de Novo HER2 + MBC in the Netherlands between 2008 and 2017. No change in metastatic presentation was observed over time, suggesting the improved OS is most likely explained by treatment improvements.
Authors
- Adri C. Voogd (ORCID: https://orcid.org/0000-0002-8041-2720)
- Thiemo J. A. van Nijnatten (ORCID: https://orcid.org/0000-0002-6431-3538)
- Karlijn Susanna Francisca Maria Hermans (ORCID: https://orcid.org/0000-0002-7629-0820)
- Sandra M. E. Geurts (ORCID: https://orcid.org/0000-0002-4265-9968)
- Marie-Jeanne T. F. D. Vrancken Peeters (ORCID: https://orcid.org/0000-0003-4472-4257)
- Loes F. S. Kooreman (ORCID: https://orcid.org/0000-0001-8226-8665)
- Vivianne C. G. Tjan‐Heijnen (ORCID: https://orcid.org/0000-0002-3935-7440)
- Nan Ding (ORCID: https://orcid.org/0000-0003-3116-7498)
- Sabine Siesling (ORCID: https://orcid.org/0000-0002-0273-824X)
- Jolien Tol
- Sanne Engelen
Institutions
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- Oncode Institute (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Jeroen Bosch Ziekenhuis (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1016/j.ejca.2025.115475
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 3.14